Fiona Simpkins, M.D.
Hilarie L. and Mitchell L. Morgan President's Distinguished Professor in Women's Health
Attending Physician, Gynecologic Oncology, Department of Ob/Gyn, Hospital of the University of Pennsylvania, Philadelphia, PA
Attending Physician, Gynecologic Oncology, Department of Ob/Gyn, Pennsylvania Hospital, Philadelphia, PA
Active Staff, Gynecologic Oncology, Department of Ob/Gyn, Chester County Hospital, West Chester, PA
Director of Clinical & Translational Gynecologic Oncology Research, Penn Medicine Health System
Department: Obstetrics and Gynecology
Contact information
Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine
3400 Civic Center Blvd., 3rd Floor West
Philadelphia, PA 19104
3400 Civic Center Blvd., 3rd Floor West
Philadelphia, PA 19104
Office: 215-662-3318
Fax: 215-349-5849
Fax: 215-349-5849
Education:
B.S (Biology)
University of California, Los Angeles, CA, 1993.
(Clinical Research Training Award)
University of California, Los Angeles, CA, 1995.
M.D.
Temple University School of Medicine, Philadelphia, PA, 1999.
Permanent linkB.S (Biology)
University of California, Los Angeles, CA, 1993.
(Clinical Research Training Award)
University of California, Los Angeles, CA, 1995.
M.D.
Temple University School of Medicine, Philadelphia, PA, 1999.
Selected Publications
Smith AJB, Spataro S, Heintz J, Simpkins F, Ko EM: Disparities in clinical drug trial participation in endometrial cancer: a real-world analysis. Am J Obstet Gynecol. Apr 2025.Xu H, George E, Gallo D, Medvedev S, Wang X, Kryczka R, Hyer ML, Fourtounis J, Stocco R, Aguado-Fraile E, Petrone A, Yin SY, Shiwram A, Anderson M, Kim H, Liu F, Marshall CG, Simpkins F: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Nature Communications Apr 2025.
Smith AJ, Pancoe S, Lynch MP, Wachlin M, Powell K, Hinkle SN, Koelper NC, Doherty M, Bekelman JE, Simpkins F, Ko EM: Rideshare services for transportation assistance in gynecologic oncology: a quality improvement study. BMC Health Serv Res Feb 2025.
Kim D, Chung H, Liu W, Jeong K, Ozmen TY, Ozmen F, Rames MJ, Kim S, Guo X, Jameson N, de Jong PR, Yea S, Harford L, Li J, Mathews CA, Doroshow DB, Charles VJ, Kim D, Fischer K, Samatar AA, Jubb A, Bunker KD, Blackwell K, Simpkins F, Meric-Bernstam F, Mills GB, Harismendy O, Ma J, Lackner MR: Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers. NPJ Precis Oncol Jan 2025.
Liu YL, Mathews CA, Simpkins F, Cadoo KA, Provencher D, McCormick CC, ElNaggar AC, Altman AD, Gilbert L, Black D, Kabil N, Taylor RN, Barnicle A, Munley JY, Aghajanian C: Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis. Cancer Jan 2025.
Weeks JK, Pantel AR, Gitto SB, Liu F, Schubert EK, Pryma DA, Farwell MD, Mankoff DA, Mach RH, Simpkins F, Lin LL: [18F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [18F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status. J Nucl Med Jan 2025.
Barnicle A, Ray-Coquard I, Rouleau E, Cadoo K, Simpkins F, Aghajanian C, Leary A, Poveda A, Lheureux S, Pujade-Lauraine E, You B, Ledermann J, Matulonis U, Gourley C, Timms KM, Lai Z, Hodgson DR, Elks CE, Dearden S, Egile C, Lao-Sirieix P, Harrington EA, Brown JS: Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib. Genome Med Dec 2024.
Boland MR, Tubridy E, Solorzano SS, Simpkins F, Smith AJB, Ko EM: Geographic Disparities in Gynecologic Oncology Clinical Trial Availability in the US. JAMA Netw Open Nov 2024.
Kinose Y, Xu H, Kim H, Kumar S, Shan X, George E, Wang X, Medvedev S, Ferman B, Gitto SB, Whicker M, D'Andrea K, Wubbenhorst B, Hallberg D, O'Connor M, Schwartz LE, Hwang WT, Nathanson KL, Mills GB, Velculescu VE, Wang TL, Brown EJ, Drapkin R, Simpkins F.: Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer. under review Nature Communications Page: 27:rs.3.rs-3314138. doi: 10.21203/rs.3.rs-3314138/v1. Aug 2024.
Fiona Simpkins, Dimitrios Nasioudis, Stephanie L. Wethington, Lainie P. Martin, Janos L. Tanyi, Nawar A. Latif, Drew A. Torigian, Dalia K. Omran, Diego Rodriguez, Simon Smith, Emma Dean, Susan M. Domchek, Ronny Drapkin, Ie-Ming Shih, Eric J. Brown, Wei-Ting Hwang, Deborah K. Armstrong, Geoffrey Shapiro, Stephanie Gaillard, Robert L. Giuntoli II, Joyce F. Liu : Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (Cohort A). ASCO presentation (ASCO Anual Meeting, June, 2024, Chicago, USA: JCO Abstracts, June, 2024 June 2024.